We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

ccfDNA 101: Emerging Trends in Oncology Research

Doug White graduated from University of Wisconsin Madison with a Master’s Degree in Biochemistry and has been a Promega scientist for 25 years. While at Promega, he’s developed multiple key products including PepTag®, IsoQuant®, PureYield™ Midi and Maxipreps, and various ReliaPrep™ Nucleic Acid Purification Kits.

  • Douglas White

  • Research Scientist
    Promega Corporation

Tuesday, July 30, 2019

ccfDNA Webinar Series: The Basics and Beyond

Research in circulating cell-free DNA (ccfDNA) has become a key area of interest in the study of normal and disease states.

In Part 1 of 3 ccfDNA webinars, we will build upon the basics of ccfDNA and discuss topics, such as:

  • The history of ccfDNA
  • How do laboratories commonly extract ccfDNA
  • What are typical applications for ccfDNA

Don't forget to register to the next parts of the series:

Part 2 - ccfDNA Workflows: Honing in on the Target
Part 3 - ccfDNA In the Lab: Optimizing Purification for Sequencing

Additional Information:

Circulating cell-free DNA (ccfDNA) found in plasma and other bodily fluids shows great promise as a source of easily accessible DNA-based information. Research is giving rise to the possibility of liquid biopsies that would eliminate the need for invasive tissue collection. We will discuss ccfDNA in relation to the other molecules commonly referred to as liquid biopsy. When working with ccfDNA there are many considerations and we will discuss factors for sample collection from blood, expected recovery (yields) of ccfDNA and thoughts on the detection of rare events given expected yields and the frequency of mutational events vs. the sensitivity of various downstream assays.